Key result
Disease modifying therapies make relapses less common and severe in patients with relapse remitting multiple sclerosis.
Why the study?
Do disease modifying therapies improve benefit and acceptability in patients with relapse remitting multiple sclerosis?
Do disease modifying therapies improve benefit and acceptability in patients with relapse remitting multiple sclerosis?
This article summarizes and appraises Cochrane systematic review evidence regarding the benefit and acceptability of disease modifying therapies for relapse remitting multiple sclerosis.
Answers are grounded in this paper and cite their sources.
Supports disease modifying therapy benefits in relapsing-remitting multiple sclerosis; leaves open acceptability trade-offs and head-to-head comparisons.
Disease modifying therapies are available for the treatment of relapse remitting multiple sclerosis, making relapses less common and severe. A Cochrane systematic review was undertaken to compare their benefit and acceptability. This article summarises and appraises the review evidence.
No takes yet. Share an insight, caveat, or question.
Harrison et al. (2022) studied this question. Disease modifying therapies make relapses less common and severe in patients with relapse remitting multiple sclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: